About

Selux Diagnostics focuses on antibiotic susceptibility testing (AST) to address the growing issue of antimicrobial resistance (AMR). The company provides healthcare providers, such as hospitals, with rapid and comprehensive testing services that evaluate the effectiveness of various antibiotics against bacteria. This technology allows for simultaneous testing against all relevant antibiotics, which is a notable advancement in a field that has seen little progress in recent years. By delivering faster diagnostic results, Selux helps ensure that patients receive the correct antibiotics, reducing the risk of ineffective treatments and the over-prescription of antibiotics. The goal of Selux Diagnostics is to preserve the effectiveness of antibiotics for future generations and combat the global health crisis posed by AMR.

Simplify's Take

What believers are saying

• Recent $48 million funding round supports aggressive expansion and product development.
• FDA clearance for Gram-Negative Panel enhances Selux's comprehensive AST platform.
• Growing demand for rapid diagnostics boosts Selux's market potential.

What critics are saying

• Increased competition in the rapid AST market threatens Selux's market share.
• Reliance on continuous funding poses financial risks if future funding is challenging.
• Potential FDA approval delays could hinder product expansion and competitiveness.

What makes Selux Diagnostics unique

• Selux offers the only single-platform technology for rapid AST from blood cultures.
• Their Next Generation Phenotyping platform provides personalized antimicrobial therapies quickly.
• Selux's AST technology tests against all commercially relevant antibiotics simultaneously.

Help us improve and share your feedback! Did you find this helpful?

YesNo